Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6760625 | 0.80 | KEAP1 (0.57) | KEAP1 | |
| SCHEMBL2127567 | 0.76 | KEAP1 (0.61) | CA2SLC22A12PTGS1PTGS2KEAP1 | |
| SCHEMBL3482992 | 0.73 | IDO1 (0.38) | KEAP1 | |
| SCHEMBL6181471 | 0.72 | CA2 (0.44) | CA2SLC22A12PTGS1PTGS2CA1 | |
| SCHEMBL250357 | 0.68 | KEAP1 (0.54) | SLC22A12PTGS1PTGS2KEAP1 | |
| SCHEMBL4153477 | 0.67 | CA2 (0.45) | CA2PTGS1PTGS2CA1PTPN1 | |
| SCHEMBL1451591 | 0.67 | KMT2A (0.50) | — | |
| SCHEMBL19042419 | 0.67 | KEAP1 (0.57) | CA2CA1KEAP1 | |
| SCHEMBL12054691 | 0.66 | CA2 (0.66) | CA2PTGS1PTGS2CA1 | |
| SCHEMBL1370545 | 0.66 | AXL (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1291345-B1 | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors | WARNER LAMBERT CO (US) | 2005-11-30 | — | — | EP | disclosed |
| US-6924276-B2 | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-08-02 | — | — | US | disclosed |
| US-20040039208-A1 | Process for making n-aryl-anthranilic acids and their derivatives | CHEN MICHAEL HUAI GU (US) | 2004-02-26 | — | — | US | disclosed |
| EP-1313694-A1 | PROCESS FOR MAKING N-ARYL-ANTHRANILIC ACIDS AND THEIR DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20030087924-A1 | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors | SORENSON RODERICK JOSEPH (US) | 2003-05-08 | — | — | US | disclosed |
| EP-1291345-A1 | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2002018319-A1 | PROCESS FOR MAKING N-ARYL-ANTHRANILIC ACIDS AND THEIR DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039208-A1 | Process for making n-aryl-anthranilic acids and their derivatives | AADAC, AHR, AADAT | CA2 1208/4885SLC22A12 1747/4885PTGS1 1935/4885 |
| US-20030087924-A1 | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors | MMP13, MMP3, MMP9 | CA2 24/4885SLC22A12 1015/4885PTGS1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.